Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

By G. Giaccone, R. Herbst, C. Manegold, G. Scagliotti, R. Rosell, Vincent A. Miller, R. Natale, J. Schiller, J. von Pawel, A. Płużańska and 8 more. Journal of Clinical Oncology, 2004

1,793 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/46ce68f3d03bb261380b84aa42d00f3a74e7235f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. D. Stewart
2. William Pao
3. K. Imai
4. A. Takaoka

In Pulmonary and Respiratory Medicine

1. B. Hughes
2. B. Chan
3. D. Stewart
4. William Pao
5. K. Imai
6. A. Takaoka

Citations in the corpus

• Chemotherapy and the war on cancer (2005, background): “, but failed to increase activity of chemotherapy in large randomized trial”
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, methodology): “platinum-based doublets (both were three-arm studies with two different doses of gefitinib v chemotherapy alone).(89,90) In both trials,”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “The INTACT 1 (48) and INTACT 2 (49) looked at gefitinib whereas the TRIBUTE (50) and TALENT (51) trials used erlotinib.”
• Mechanisms of resistance to cisplatin and carboplatin. (2007, background): “[276] Giaccone G, Herbst RS, Manegold C, et al.”
• Comparing antibody and small-molecule therapies for cancer (2006, background): “The combination of gefitinib with two different chemotherapy regimens in advanced NSCLC did not result in any additive effects over chemotherapy alone in two large randomized studie”